by Julia Moióli, FAPESP Scientists believe the rising incidence of atopic dermatitis could be linked to alterations in gut microbiome composition, diet and lifestyle. Credit: James Heilman/Wikimedia Commons Atopic dermatitis (AD) is a chronic inflammatory skin disease whose main symptoms are redness, swelling, and itchy rashes. It is more common in people with a genetic predisposition....
by National Jewish Health Credit: Unsplash/CC0 Public DomainPatients with atopic dermatitis, the most common inflammatory skin disease in the general population, often have vascular changes that lead to a loss of proteins in their skin and symptoms like oozing, bleeding, infection and redness. In a recent study, researchers at National Jewish Health tested a medication...
by Yale School of Medicine Atopic dermatitis. Credit: AfroBrazilian/Wikimedia Commons, CC BY-SA Atopic dermatitis (AD) is a chronic, inflammatory skin disorder that has well-established associations with depression and anxiety. A new Yale School of Medicine study, published in Archives of Dermatological Research, finds AD is also associated with increased risk for schizophrenia and schizoaffective disorder. Schizophrenia is...
by Tohoku University Images of skin lesions can vary significantly depending on the distance between the lesion and the imaging device. By minimizing the imaging bias caused by distance, the accuracy of skin lesion differentiation can be enhanced. Credit: Yuta Yanagisawa et al Atopic dermatitis skin lesions and the lesions produced by infectious complications of...
Reviewed by Emily Henderson, B.Sc.Dec 12 2022 Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab-;a novel, patient-tailored monoclonal antibody therapy-;showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet. The researchers said the results indicate...
UNIVERSITY OF PENNSYLVANIA Atopic dermatitis, a common skin condition affecting both children and adults, is often thought of as an inflammatory disease that arises from a breakdown in the barrier function of the skin. Now a new study pinpoints a cascade of inflammatory signaling that precedes the appearance of skin ulcers, shedding light on the...
INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE Upadacinib is a new drug for the treatment of adults and adolescents aged 12 years and older with moderate to severe atopic dermatitis who are candidates for systemic therapy. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now...
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) SINGAPORE IMAGE: IMMUNOFLUORESCENCE LABELING OF HEALTHY AND PSORIATIC PATIENT SKIN. DOTTED LINE SHOWS THE DERMAL–EPIDERMAL JUNCTION. HLA-DR: GREEN, GLUT3 (SLC2A3): RED, AND DAPI: BLUE. SCALE BAR = 100 ΜM (LOW MAGNIFICATION) AND 10 ΜM (HIGH MAGNIFICATION). CREDIT: PLEASE CREDIT IMAGE TO A*STAR SINGAPORE IMMUNOLOGY NETWORK (SIGN) AND SKIN...
Topical corticosteroids should be applied just once daily to treat atopic dermatitis (AD), and prescribing oral antihistamines should be phased out, dermatologists recommend in a new review. The authors also encourage four other treatment practices for AD and dissuade use of well-known interventions that have shown no clinical benefit. Dr Hywel Williams These recommendations give patients “safer and more effective approaches...
By Marilynn Larkin June 04, 2021 NEW YORK (Reuters Health) – Two-phase 3, placebo-controlled studies suggest the oral Janus kinase (JAK) inhibitor upadacitinib is effective for moderate-to-severe atopic dermatitis (AD), both alone and with topical corticosteroids. “The results are highly robust and consistent among studies with really high efficacy and clearance rates that we have not seen...
